1. Name Of The Medicinal Product
Lemsip Chesty Cough 50mg/5ml oral solution
Lemsip Mucus Cough 50mg/5ml oral solution
2. Qualitative And Quantitative Composition
Guaifenesin 50mg/5ml
Excipient(s):
|
|
|
|
For full list of excipients, see section 6.1.
3. Pharmaceutical Form
Oral solution
4. Clinical Particulars
4.1 Therapeutic Indications
Symptomatic relief of deep chesty coughs and to soothe the throat.
4.2 Posology And Method Of Administration
For oral administration.
To be taken three or four times daily.
Adults and children over 12: two to four 5ml spoonfuls.
Under 12 years: On medical advice only
4.3 Contraindications
Hypersensitivity to guaifenesin or to any of the excipients.
4.4 Special Warnings And Precautions For Use
This medicine contains 0.16 mmol (or 3.66 mg) sodium per 5 ml dose. To be taken into consideration by patients on a controlled sodium diet.
Contains 3.965 g of sucrose per 5 ml dose. This should be taken into account in patients with diabetes mellitus.
Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction
If urine is collected within 24 hours of a dose of the medicinal product, a metabolite of guaifenesin may cause a colour interference with laboratory determinations of urinary 5-hydroxyindoleacetic acid (5-HIAA) and vanillylmandelic acid (VMA).
Guaifenesin may increase the rate of absorption of paracetamol.
4.6 Pregnancy And Lactation
Guaifenesin has been linked with an increased risk of neural tube defects in a small number of women with febrile illness in the first trimester of pregnancy. The product should be used in pregnancy only if the benefits outweigh this risk. There is no information on use in lactation.
4.7 Effects On Ability To Drive And Use Machines
None.
4.8 Undesirable Effects
Guaifenesin has occasionally been reported to cause gastro-intestinal discomfort, nausea and vomiting, particularly in very high doses. Also, hypersensitivity reactions may occur.
4.9 Overdose
Very large doses may cause nausea and vomiting. The drug is, however, rapidly metabolised and excreted in the urine. Patients should be kept under observation and treated symptomatically.
5. Pharmacological Properties
5.1 Pharmacodynamic Properties
|
|
|
|
Guaifenesin
Guaifenesin is reported to reduce the viscosity of tenacious sputum and is used as an expectorant.
The active ingredient is not known to cause sedation.
5.2 Pharmacokinetic Properties
Guaiphenesin
Guaiphenesin is absorbed from the gastrointestinal tract. It is metabolised and excreted in the urine.
5.3 Preclinical Safety Data
No preclinical findings of relevance to the prescriber have been reported.
6. Pharmaceutical Particulars
6.1 List Of Excipients
Sucrose
Glycerol,
Toluflavour solution,
Sodium benzoate,
Citric acid anhydrous granular,
Sodium citrate,
Lemon oil terpeneless,
Isopropyl alcohol,
Purified water
Sodium cyclamate.
6.2 Incompatibilities
None known.
6.3 Shelf Life
Three years
6.4 Special Precautions For Storage
None
6.5 Nature And Contents Of Container
Amber glass bottles with a polypropylene cap with a child resistant closure with a polyethylene tamper-evident band with expanded polyethylene wad. Pack size: 100 ml, 150 ml, 200 ml and 300 ml.
6.6 Special Precautions For Disposal And Other Handling
To be taken orally at the recommended dose.
7. Marketing Authorisation Holder
Reckitt Benckiser Healthcare (UK) Limited
Dansom Lane
Hull
HU8 7DS
8. Marketing Authorisation Number(S)
PL 00063/0036
9. Date Of First Authorisation/Renewal Of The Authorisation
24th April 1995
10. Date Of Revision Of The Text
31/08/2011
No comments:
Post a Comment